clinical trial · NCT04892017
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC·phase1·terminated·n = 91
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid TumorInlexisertibTrametinibBinimetinibSotorasib
brief summary
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
started
Jun 15, 2021
primary completion
Mar 30, 2026
completion
Mar 30, 2026
last updated
Apr 8, 2026
official title
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol